EMV

EMVision is advancing a CRC-P–funded clinical study to demonstrate bedside stroke diagnosis in remote Australian hospitals, addressing a real unmet need with global relevance (US CAHs, rural worldwide); the $337k payment and completed site visits mark tangible progress, but this is pre-efficacy work—no efficacy data, no regulatory milestone, and no commercial traction reported.

EMVision has crossed 200 patients in its pivotal emu™ brain scanner trial with zero device-related adverse events and plans to layer ischaemia detection onto the same cohort, potentially compressing FDA timeline by ~2 years. The milestone indicators recruitment acceleration and clinical traction at tier-1 US centres (Mayo, Mount Sinai, UCLA), but full enrollment and endpoint readouts remain 6–12 months away.

EMVision reported FY26 results showing revenue growth and narrowing losses as its portable brain scanner (emu™) pivotal trial advances across Mayo Clinic, UCLA and other leading US/Australian stroke centres, with FDA De Novo submission targeted for FY27 and First Responder production units due early CY27. The company remains well-funded with $17.1m cash plus $4.6m in non-dilutive grants, prioritising regulatory clearance and pre-commercialisation groundwork in a multibillion-dollar stroke diagnostics market.